XML 18 R2.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Apr. 01, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 723,269 $ 647,169
Short-term investments 847,060 819,905
Trade receivables, net 190,614 282,650
Inventory 28,467 27,493
Prepaid expenses and other current assets 53,333 57,530
Total current assets 1,842,743 1,834,747
Long-term investments 404,535 371,112
Property and equipment, net 106,169 104,031
Deferred tax assets, net 98,001 111,663
Goodwill 63,684 63,684
Other long-term assets 138,986 131,002
Total assets 2,654,118 2,616,239
Current liabilities:    
Accounts payable 17,285 24,258
Accrued compensation and benefits 42,768 61,969
Accrued clinical trial liabilities 82,885 77,544
Rebates and fees due to customers 49,997 33,700
Accrued collaboration liabilities 32,492 86,753
Other current liabilities 63,652 53,366
Total current liabilities 289,079 337,590
Long-term portion of deferred revenues 8,035 8,739
Long-term portion of operating lease liabilities 50,636 51,272
Other long-term liabilities 12,517 8,023
Total liabilities 360,267 405,624
Commitments and contingencies
Stockholders' equity    
Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued 0 0
Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 320,268 and 318,842 at March 31, 2022, and December 31, 2021, respectively 320 319
Additional paid-in capital 2,448,130 2,427,561
Accumulated other comprehensive loss (6,665) (758)
Accumulated deficit (147,934) (216,507)
Total stockholders' equity 2,293,851 2,210,615
Total liabilities and stockholders' equity $ 2,654,118 $ 2,616,239